news flash·2025-06-27 09:00Core Viewpoint - The company XinHua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the supplemental application of Adenosylcobalamin capsules, allowing the transfer of the marketing authorization holder [1] Group 1: Regulatory Approval - The approval notification allows the company to transfer the supplemental application without the need for board or shareholder meeting reviews, in accordance with the Shenzhen Stock Exchange listing rules and the company's articles of association [1] - The transaction does not constitute a related party transaction or a major asset restructuring as defined by the regulations [1] Group 2: Product Indications - Adenosylcobalamin capsules are primarily indicated for the treatment of megaloblastic anemia, nutritional anemia, anemia during pregnancy, multiple neuritis, radiculitis, trigeminal neuralgia, sciatica, and nerve paralysis [1] - The product can also be used as an adjunctive treatment for nutritional disorders and leukopenia caused by radiation and drugs [1]